Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

Diabetes Mellitus, Type 1 Clinical Trial

— Daily Life  

Official title:

An Open-label, Randomized, Two-period Crossover Study to Evaluate the Safety Use of the InsuPatch Device in Daily Life Conditions.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01283425
• Other study ID #: G080106/B
• Status: Completed
• Phase: Phase 4
• First received: January 19, 2011
• Last updated: September 3, 2014
• Start date: February 2011
• Est. completion date: April 2012

Study information

• Verified date: April 2012
• Source: Insuline Medical Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationIsrael: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The study is an open-label, randomized, two-period crossover study. Up to one hundred and twenty (120) subjects with type 1 diabetes mellitus (T1DM) who use the MiniMed paradigm insulin pump, who meet the inclusion/exclusion criteria and who provide written Informed Consent will be enrolled in the study. The aim of the study is to examine the safety of the InsuPatch device in a home use setting. Mild Hypoglycemia,hyperglycemia and Adverse events will be compared between two phases of the study : 3 months with the use of the device and 3 months without the use of the device.

Description:

The primary objective of this study is to show that safety parameters are similar, when delivering insulin subcutaneously in subjects with type I diabetes using the InsuPatch device along with the Medtronic Minimed Paradigm insulin infusion pump and the Medtronic Minimed Quick-Set® infusion set compared to subcutaneous insulin delivered with the above mentioned equipment, without the InsuPatch device.

The participation of each subject in this study will be up to seven months and will include three phases: one week Run in phase , 3 months with device use and 3 months without device use. Study will include 4 clinic visits and bi weekly calls. During the entire study the subjects will be requested to preform at least 5 blood glucose self measurements and record results in a logbook.At each visit blood will be drawn for HBA1C test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 147
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Subject's age range 18- 65 years old (including 18 and 65 years old)

2. BMI: 18-35 kg/m2

3. Type 1 diabetes patients using a MiniMed Paradigm insulin pump for at least six months, who are administering insulin Lispro or Insulin Aspart and are using the Quick-set infusion set.

4. Patients with T1DM whose HbA1c values are at or below 9.5% (including 9.5%) and at or above 6% (including 6%).

5. Agree to sign consent form before any study-specific tests or procedures are to be performed.

6. Subject's completed at least 14 measurements during the Run-In Phase and readiness to continue the study with at least 5 blood glucose recordings per day and keep a logbook during the study period.

7. Subject readiness to use the InsuPatch, his comprehension of the study requirements and treatment procedures.

8. Willingness to comply with all specified follow-up evaluations.

Exclusion Criteria:

1. Pregnancy

2. Breast feeding women.

3. Alcohol addiction

4. CABG (Coronary Artery Bypass Graft), MI (Myocardial Infarction) or active Ischemic Heart Disease prior to study date.

5. CVA (cardiovascular accident) or TIA (transient ischemic accident) events prior to study date.

6. Uncontrolled hypertension (blood pressure in mm HG >160 systolic or > 95 diastolic) .

7. Any history of gastroparesis or enteroparesis.

8. Abnormal kidney and/ or liver function tests. (Defined as Creatinine >1.5 mg/dL, liver tests> 2 times the upper limit of normal).

9. A severe hypoglycemic event requiring a glucagon injection or intravenous glucose infusion within the last six months prior to study inclusion.

10. Hypoglycemia unawareness.

11. Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior to study inclusion.

12. Psychological incompetence.

13. Signs of drug abuse.

14. Any other clinical condition or history, which seems to be relevant for the Principle Investigator to disqualify a participant.

15. Subjects with diminished skin integrity, Excessive fibrosis, lipo-hypertrophy or eczema at infusion sites.

16. Heat sensitive subjects.

17. Subjects involved in or planning to participate in other studies.

18. Subjects using any drug therapy, other than insulin, to control their blood glucose levels.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1

Intervention

Device:
• InsuPatch
Heaters for single use and a permanent control unit.

Locations

Country	Name	City	State
Israel	Soroka Medical Center	Beer Sheva
Israel	Hillel Yaffe	Hadera
Israel	Rambam Medical Center	Haifa
Israel	Wolfson Medical Center	Holon
Israel	Haddasah Medical Organization	Jerusalem
Israel	Schneider Children's hospital	Petah Tikva
Israel	Sheba Medical Center	Ramat Gan
United States	Mills-Peninsula Health Services	San Mateo	California

Sponsors (1)

Lead Sponsor	Collaborator
Insuline Medical Ltd.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.	The confirmatory safety endpoint is, for each subject, frequency of mild hypoglycemia events (Blood Glucose<60mg/dl) with InsuPatch and without.; The number of events will be assessed from subject logbook and will be compared between two arms.	safety will be assesed after 6 months at the study completion	Yes
Secondary	Frequency of hyperglycemic events (BG>300 mg/dl, Fasting BG>250 mg/dl) with InsuPatch and without.	Frequency of hyperglycemic events (BG>300 mg/dl, Fasting BG>250 mg/dl) with InsuPatch and without.The number of events will be assesed from subject logbook and will be compared between two arms.	safety will be assesed after 6 months at the study completion	Yes
Secondary	Adverse events (AE's) count with InsuPatch and without.	Adverse events (AE's) whether or not deemed related to study device with InsuPatch and without.The number of events will be assesed dering the subject visits and bi-weekly calls and will be compared between two arms.	safety will be assesed after 6 months at the study completion	Yes

External Links

•   Link